Product Description
Nā Kiʻi Kumu Semaglutide Raw
| Product Name: | Semaglutide |
| Helu CAS: | 910463-68-2 |
| Nā Kaulike Molecular: | C187H291N45O59 |
| Molecular Weight: | 4113.58g / mol |
| Wahi Manaʻo: | 34-39 ° C |
| kala like 'ole: | Keʻokeʻo |
| Hōʻoia Kōkua: | E mālama i ka 8°C-20°C, pale mai ka makū a me ka malamalama |
He aha ka Semaglutide?
ʻO Semaglutide kahi glucagon-like peptide-1 receptor agonist i hoʻohana ʻia i nā poʻe me ka maʻi diabetes type 2 i mea hoʻohui i ka meaʻai a me ka hoʻomaʻamaʻa e hoʻomaikaʻi ai i ka mana glycemic..Semaglutide he mimic GLP-1 loaʻa ka 94% sequence homology i ke kanaka GLP-1. Hiki iā ia ke hoʻopaʻa i ka mea hoʻokipa GLP-1 a hoʻoulu i ka mea hoʻokipa e hoʻohaʻahaʻa i ke koko koko ma o ka hoʻonui ʻana i ka hana insulin a me ka hoʻohaʻahaʻa ʻana i ka huna ʻana o ka glucagon ma ke ʻano he mea loaʻa GLP-1. agonist. Eia kekahi, hiki i ka semaglutide ke hana ma ka digestive tract ma ka hoʻopaneʻe ʻana i ka hoʻohemo ʻana o ka ʻōpū e hoʻoulu i ka piha; ma ka lolo ma ke kāohi ʻana i ka ʻai; a ma ka ʻōnaehana holo kaʻa ma ka hoʻoponopono ʻana i ka intima i hōʻino ʻia a me ka hoʻomaikaʻi ʻana i ka hana endothelial.
Pehea e hana ai ʻo Semaglutide?
ʻO ka pauka Semaglutide He agonist o ka glucagon-like peptide-1 receptor. Hoʻonui ia i ka hana ʻana o ka insulin, he hormone e hoʻemi ana i ke kō koko koko, ma ka hoʻohālikelike ʻana i ka hopena o ka incretin glucagon-like peptide-1 (GLP-1). e hoʻoulu i ka hoʻonui ʻana o nā cell beta pancreatic, nona ke kuleana no ka hoʻokumu ʻana a me ka hoʻokuʻu ʻana o ka insulin. Eia kekahi, hiki i ka AASraw semaglutide ke hoʻemi i ka hana glucagon, kahi hormone e hoʻoulu ai i ka glycogenolysis (ka hoʻokuʻu ʻana o nā kaʻa i mālama ʻia mai ke akepaʻa) a me ka gluconeogenesis (ka ka hana ʻana o ka glucose hou). Hoʻemi ia i ka ʻai ʻana i ka meaʻai ma ke kāohi ʻana i ka pōloli a hoʻolohi i ka ʻai ʻana i loko o ka ʻōpū, kahi e kōkua ai i ka pohō kaumaha.
ʻO ka noiʻi ma Semaglutide
①Hoʻolauna
He lāʻau lapaʻau ʻo Semaglutide i hoʻomohala mua ʻia e mālama i ka maʻi maʻi. Akā naʻe, ua loaʻa ka kaulana ma ke ʻano he lāʻau hoʻemi kaumaha ma hope o ka ʻike ʻia ʻana e kōkua pono i ka poʻe e lilo i ke kaumaha, me ka lua o ke kanaka waiwai loa o ka honua, ʻo Elon Musk.Hoʻokahi-Weekly Semaglutide i nā ʻōpio me ka momona—-i hoopukaia ma ka Nūpepa Lapaʻau o ʻEnelani hou (NEJM) ua ʻike ʻo semaglutide hiki ke kōkua i nā ʻōpio momona e hoʻemi i ke kaumaha a hoʻoikaika i ke olakino naʻau.
②Nā ʻike koʻikoʻi
- ʻO ka poʻe ʻōpio obese i lawe i ka semaglutide i kēlā me kēia pule i ʻike i ka piʻi ʻana o 16.1% i ka helu kino kino (BMI) i kahi hoʻokolohua hoʻokolohua hoʻokolohua honua 3a, i hoʻohālikelike ʻia me ka piʻi ʻana o 0.6% i ka hui placebo.
- ʻO Semaglutide kahi glucagon-like peptide 1 (GLP-1) receptor agonist hiki ke hōʻemi i ka ʻai, ka meaʻai, a me ka lawe ʻana i ka calorie, e hana pono ai no ka pohō kaumaha.
- Ua hōʻike ʻia kahi hoʻokolohua lapaʻau nui he hopena kupaianaha ka semaglutide ma ke ʻano he lāʻau hoʻēmi kaumaha, me ka hui i mālama ʻia e nalowale ana i ka awelika o 15.3 kg.
- I Iune 2021, ua ʻae ka USFood and Drug Administration (FDA) i ke kūʻai aku ʻana o semaglutide (Semaglutide), kahi lāʻau hoʻemi kaumaha me kahi inoa kālepa o Wegovy.
- Ua ʻike ʻia kahi noiʻi hou ua ʻoi aku ka maikaʻi o ka semaglutide i kahi placebo ma ke ʻano o ka pohō kaumaha a me ka hoʻomaikaʻi ʻana i nā kumu pilikia cardiometabolic i nā ʻōpio obese.
- Ma hope o ka lawe ʻana i ka semaglutide, ua hoʻomaikaʻi ʻia nā mea pilikia o ka maʻi cardiovascular e like me ka pōʻai pūhaka, ka helu glucose koko HbA1c, ka nui o ka cholesterol, ka lipoprotein cholesterol haʻahaʻa haʻahaʻa a haʻahaʻa loa, triglycerides, a me nā triglycerides.
- Ua ʻoi aku ka maikaʻi o ke ola o ka hui semaglutide ma mua o ka hui placebo, no ka nui o nā helu hōʻoluʻolu kino.
③Ka hopena
Ua hōʻike ʻia ʻo Semaglutide he lāʻau lapaʻau maikaʻi no ka pohō kaumaha, a ua hōʻike ʻia ka noiʻi hou ʻana he mea pono paha ia no nā ʻōpio momona. ana ola.
Kumu kumu:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997064/
Nā pono o ka hoʻohana ʻana Semaglutide
ʻO Semaglutide kahi lāʻau lapaʻau maʻamau e hāʻawi ana i ka nui o nā pōmaikaʻi no nā poʻe me nā ʻano maʻi like ʻole.
①Ke hoʻohaʻahaʻa i nā pae koko koko
ʻO Semaglutide kahi agonist receptor GLP-1 i kūpono i ka hoʻohaʻahaʻa ʻana i nā pae glucose koko i nā poʻe me ka maʻi diabetes type 2 e kekahi mau mīkini. Hoʻopau pū ʻo Semaglutide i ka huna ʻana o ka glucagon, kahi e hōʻemi ai i ka hana glucose e ke ake.
I loko o nā hoʻokolohua lapaʻau, ua hōʻike ʻia ka semaglutide e hōʻemi nui i nā pae HbA1c, kahi hōʻailona o ka mālama ʻana i ka glucose koko lōʻihi. ka ho'āʻoʻana, ua ho'ēmiʻia ka nui o ka HbA1c ma ka 1% i ka hoʻohālikelikeʻana i kahi placebo. Ua hōʻikeʻia hoʻi ka maikaʻi o Semaglutide i ka ho'ēmiʻana i ka hoʻokēʻai plasma glucose pae a me ka postprandial glucose huakaʻi.
②E hōʻemi ana i ka pilikia o nā hanana maʻi cardiovascular
Ua hōʻike ʻia ʻo Semaglutide e hōʻemi i ka hopena o nā hanana maʻi cardiovascular koʻikoʻi (MACE) e like me ka make cardiovascular, nonfatal myocardial infarction, a me ka hōʻeha ʻole i ka make i nā pākeke me ka maʻi diabetes type 2 a ua hoʻokumu ʻia ka maʻi cardiovascular. -6 mau ho'āʻo, i hōʻike i ka emi nui o ka MACE me ka semaglutide lapaʻau i hoʻohālikelike ʻia me kahi placebo. Eia kekahi, ua hōʻike ʻia ʻo Semaglutide e hoʻomaikaʻi i kekahi mau mea pilikia cardiovascular e like me ke koko, lipid profile, a me nā hōʻailona o ka mumū i nā poʻe me ka maʻi diabetes type 6. ʻO ka hoʻāʻo ʻo SUSTAIN-2, pili ka semaglutide me ka hoʻohaʻahaʻa nui ʻana i ke koko systolic a me ka hoʻomaikaʻi ʻana i ka lipid profile, me ka hoʻemi ʻana i ka kolamu a pau, LDL cholesterol, a me nā triglycerides.
③Nalo ke kaumaha
ʻO Semaglutide he mea hoʻoemi kaumaha nui,ʻo ia hoʻi i loko o nā kānaka me ka maʻi maʻiʻole. Ke hana neiʻo Semaglutide ma ka ho'ēmiʻana i ka makemake a me ka calorie intake, e alakaʻi ana i ka emiʻana o ke kaumaha o ke kino. ʻO ka hypothalamus, ka mea e hoʻoponopono ai i ka pōloli a me ka māʻona, a hoʻemi i ka makemake e ʻai ma ka hoʻonui ʻana i ka manaʻo o ka piha.
Ua hōʻike nā hoʻokolohua lapaʻau i nā pōmaikaʻi o ka pohō kaumaha o semaglutide.Ma ka papahana STEP, nāna i loiloi i ka hoʻohana ʻana i ka semaglutide no ka mālama ʻana i ke kaumaha i nā poʻe me ka maʻi maʻi ʻole, ua pili ka semaglutide me ka pohō kaumaha nui i hoʻohālikelike ʻia me kahi placebo. ʻO ka awelika o 15% o ko lākou kaumaha kino ma mua o 68 mau pule, aʻo ka poʻe i loaʻa i ka placebo ua nalowale he 2.4%.
I ka poʻe me ka maʻi maʻi type 2, hiki i ka semaglutide ke alakaʻi i nā pōmaikaʻi pohō kaumaha. .ʻO ka poʻe i loaʻa i ka semaglutide ua nalowale ka awelika o 7 kg, aʻo ka poʻe i loaʻa i ka placebo ua nalowale he 2 kg wale nō.
④Lapaʻau ʻana i ka hōʻailona maʻi o Alzheimer
Ua hōʻike ʻia nā haʻawina preclinical he nui he mau neuroprotective ka semaglutide e kūʻē i nā pā amyloid-β i loko o kahi laina cell neuroblastoma (SH-SY5Y) kanaka, e hōʻike ana e hiki i ka semaglutide ke hoʻohaʻahaʻa i ka hōʻailona o ka maʻi o Alzheimer. Wahi a ka hoʻolaha a Novo Nordisk, aia ka hōʻailona o nā papa semaglutide no ka maʻi o Alzheimer (AD). Aia ʻelua mau hoʻokolohua Phase III honua, ʻo EVOKE a me EVOKE hoʻohui, a ma kahi o 3,700 mau mea manawaleʻa e manaʻo ʻia e kiʻi ʻia. , i ka hoʻohālikelike ʻia me kahi placebo, e loiloi i ka kiʻekiʻe o nā papa semaglutide ma ka hana cognitive i nā kumuhana me ka haʻahaʻa haʻahaʻa haʻahaʻa (MCI) a i ʻole dementia haʻahaʻa i hana ʻia e AD.
'Ōlelo Aʻo: He kī ia i ke kūʻaiʻana i ka semaglutide mai nā kumu kaulana, ināʻaʻole,ʻaʻole hiki iāʻoe ke loaʻa ka maikaʻi maikaʻi o ka semaglutide. nāu.
Nā hopena ʻaoʻao o Semaglutide?
ʻO Semaglutide, e like me nā lāʻau lapaʻau, hiki ke hana i nā hopena ʻaoʻao.
①Eia nā hopena ʻaoʻao maʻamau:
- 'O Nausea
- ʻO ka wai
- Kōkua
- ʻO kaʻehaʻeha
- Pau ka maʻi
- Ka hoʻomau
- Heʻeha
- 'Oloke
- Hoʻoponopono
②E like me nā hopena ʻaoʻao maʻamau akā ʻoi aku ka koʻikoʻi:
- Pancreatitis
- Hypoglycemia (ke koko haʻahaʻa)
- ʻO ka ʻehaʻehā o kaʻeha
- ʻO ka hoʻopiʻi ʻana i ka retinopathy diabetes
- ʻO ka maʻi Gallbladder
- Nā hopena maʻi
- ʻO nā maʻi maʻi thyroid
Notes: Hiki ke hoʻololi i ka lōʻihi o ka hopena o ka semaglutide ma muli o ke kanaka a me ka paʻakikī o nā hopena. ʻO ka nausea, ka maʻi paʻa, ka luaʻi, ka paʻa, a me ke poʻo maʻamau e hoʻoholo i loko o kekahi mau lā a hiki i ka pule. e like me AASraw, he mea koʻikoʻi.
ʻO ka Dosage a me ka hoʻokele ʻana o Semaglutide no ka ʻike
Hiki ke ʻokoʻa ke ʻano a me ka lawelawe ʻana o ka semaglutide ma muli o ka hōʻailona no ka hoʻohana ʻana. Eia kekahi mau alakaʻi maʻamau:
①Hōʻike: Type 2 Diabetes Mellitus
· Hoʻopili i lalo
He pule 1-4: 0.25 mg / pule
He pule 5 a ma mua: 0.5 mg / pule
√ Inā pono, ma hope o 4 mau pule ma ka 0.5-mg dose, e hoʻonui i ka 1 mg subcutaneously hoʻokahi pule.
√ Inā pono, ma hope o 4 mau pule ma ka 1-mg dose, e hoʻonui i ka 2 mg subcutaneously hoʻokahi pule; ʻaʻole ma mua o 2 mg / pule.
· Papa Waʻa
Lā 1-30: 3 mg / lā
ʻO ka lā 31 a ma mua: 7 mg / lā
√ Inā pono, ma hope o 30 mau lā ma ka helu 7-mg, e hoʻonui i ka 14 mg i hoʻokahi manawa i kēlā me kēia lā.
√ Nānā: Mai lawe i ʻelua papa 7-mg no ka loaʻa ʻana o kahi maʻi 14-mg
②Indication: Hoʻokele Weight Kaumaha
· Hoʻopili i lalo
He pule 1-4: 0.25 mg / pule
He pule 5-8: 0.5 mg / pule
He pule 9-12: 1 mg / pule
He pule 13-16: 1.7 mg / pule
Hebedoma 17 a ma mua aku: 2.4 mg / pule (ka nui mālama)
√ E hoʻomaka me ka haʻahaʻa haʻahaʻa a e piʻi mālie i ka nui o ka mālama ʻana e hōʻemi i nā hopena ʻino o ka ʻōpū.
√ Inā ʻaʻole hiki iā ʻoe ke ʻae i kahi maʻi i ka wā o ka piʻi ʻana, e noʻonoʻo e lohi i ka piʻi ʻana o ka maʻi no 4 pule.
√ Inā hiki ʻole ke ʻae i ka nui o ka mālama ʻana o 2.4 mg i hoʻokahi pule i kēlā me kēia pule, hiki ke emi iki i ka 1.7 mg i hoʻokahi pule i kēlā me kēia pule no ka lōʻihi o 4 mau pule; ma hope o 4 mau pule, e hoʻonui hou i ka mālama ʻana i ka 2.4 mg i hoʻokahi pule; hoʻopau inā ʻaʻole ʻae ʻia ma hope o ka hoʻāʻo ʻelua.
√ Nānā: Hiki ke hoʻololi i ka dosage a me ka lawelaweʻana o ka semaglutide ma muli o ka hōʻailona no ka hoʻohana.
Ma hea e kūʻai ai iā Semaglutide?
ʻO Semaglutide, kahi lāʻau lapaʻau i ʻimi nui ʻia no ka mālama ʻana i ka maʻi diabetes type 2, ua lilo i mea kaulana loa i waena o nā poʻe maʻi e ʻimi nei i nā hopena kūpono e mālama ai i ko lākou kūlana. Hāʻawi nā paepae kikohoʻe i nā mea kūʻai aku i ka manawa kūpono e hoʻohālikelike i nā kumukūʻai, heluhelu i nā loiloi, a me ke komo ʻana i nā koho he nui e kūpono i ko lākou mau pono. Hoʻololi i ko lākou olakino. Ma ka hana ʻana i ka noiʻi ʻana a me ke koho ʻana i kahi mea kūʻai aku kaulana a hōʻoia ʻia, hiki i nā kānaka ke kūʻai wiwo ʻole i ka semaglutide ma ka pūnaewele a mālama pono i kā lākou maʻi diabetes me ka maʻalahi.
KANAKA Ke manaʻo nei e hana i ka abd e hoʻolako ana i nā mea waena a me nā mea lāʻau lapaʻau ikaika (API), he mea hilinaʻi i ka mea hoʻolako i ka semaglutide kiʻekiʻe a me nā huahana pili ʻē aʻe. ma ke kūʻai ʻana ma AASraw, hiki i nā poʻe e ʻimi ana i ka semaglutide ke hauʻoli i kahi ʻike kūʻai kūpono, palekana, a hilinaʻi hoʻi, ʻoiai e pōmaikaʻi ana i ko lākou ʻike nui a me ka ʻike ma ke kahua.
Hōʻike hoʻāʻo Semaglutide-HNMR
He aha ka HNMR a He aha ka HNMR spectrum e haʻi aku iā ʻoe? ʻO H Nuclear Magnetic Resonance (NMR) spectroscopy kahi ʻenehana kemika analytical i hoʻohana ʻia i ka hoʻokele maikaʻi a me ka noiʻi no ka hoʻoholo ʻana i ka ʻike a me ka maʻemaʻe o kahi laʻana a me kona ʻano molekala..No ka laʻana, hiki i ka NMR ke kālailai helu i nā huila i ʻike ʻia. i ka hoʻonā a me ke aʻo ʻana i nā waiwai kino ma ka pae molekala e like me ka hoʻololi conformational, hoʻololi i ka pae, solubility, a me ka diffusion.
Semaglutide-COA
Pehea e kūʻai ai iā Semaglutide mai AASraw?
❶E hoʻokaʻaʻike mai iā mākou ma kā mākou ʻōnaehana nīnau leka uila, a i ʻole e waiho i kāu helu whatsapp iā mākou, e hoʻopili kā mākou mea kūʻai aku (CSR) me ʻoe i loko o 12 mau hola.
❷E hāʻawi mai iā mākou i kāu helu a me kāu helu wahi i nīnau ʻia.
❸Na kā mākou CSR e hāʻawi iā ʻoe i ka ʻōlelo, ka manawa uku, ka helu ʻimi, nā ala hoʻouna a me ka lā i manaʻo ʻia (ETA).
❹E uku ʻia a hoʻouna ʻia nā waiwai i loko o 12 mau hola.
❺ Loaʻa nā waiwai a hāʻawi i nā manaʻo.
Mea kākau o kēia ʻatikala:
Kauka Monique Ua puka 'o Hong mai ke Kula Nui o UK Imperial College London Faculty of Medicine
Mea kākau moʻolelo puke moʻolelo ʻepekema:
1. Aihua Li
Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong, China
2. Tae Suk Lee
School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi 16419, Republic of Korea
3. Saullo Queiroz Silveira MD
Department of Anesthesiology, Vila Nova Star Hospital / Rede D’Or – CMA Anesthesia group, São Paulo, SP, Brazil
4. Fabiane Ferreira Martins
Laboratory of Morphometry, Metabolism, and Cardiovascular Diseases, Biomedical Center, Institute of Biology, The University of the State of Rio de Janeiro, Rio de Janeiro, Brazil
ʻAʻole ʻae kēia kauka/ ʻepekema i ke kūʻai, kūʻai ʻana, a hoʻohana paha i kēia huahana no kekahi kumu. ʻAʻohe pili a pili ʻole ʻo Aasraw, i hōʻike ʻia a i ʻole, me kēia kauka. ʻO ke kumu o ka haʻi ʻana i kēia kauka, ʻo ia ka hoʻomaikaʻi, hoʻomaikaʻi a hoʻomaikaʻi i ka hana noiʻi a me ka hoʻomohala piha i hana ʻia e nā ʻepekema e hana nei i kēia mea.
Reference:
[1] Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, Hurtado MD, Acosta A.Nā hopena o ke kaumaha i hui pū ʻia me ka mālama ʻana iā Semaglutide no nā maʻi me ke kaumaha a i ʻole ka momona.JAMA Netw Open.2022 Sep 1;5(9):e2231982.
[2] Wilding JPH,Batterham RL,Davies M,Van Gaal LF,Kandler K,Konakli K,Lingvay I,McGowan BM,Oral TK,Rosenstock J,Wadden TA,Wharton S,Yokote K,Kushner RF; KANAWAI 1 Hui Haawina.Loaʻa hou ke kaumaha a me nā hopena cardiometabolic ma hope o ka haʻalele ʻana o semaglutide: ʻO ka hoʻonui hoʻāʻo STEP 1.Diabetes Obes Metab.2022 Aug;24(8):1553-1564.
[3] Garvey WT,Batterham RL,Bhatta M,Buscemi S,Christensen LN,Frias JP,Jódar E,Kandler K,Rigas G,Wadden TA,Wharton S; STEP 5 Study Group. Nā hopena ʻelua makahiki o ka semaglutide i nā poʻe mākua me ke kaumaha a i ʻole ka momona: ka hoʻāʻo STEP 5. Nat Med.2022 Oct; 28(10):2083-2091.
[4] Knudsen LB, Lau J. ʻO ka ʻike a me ka hoʻomohala ʻana o Liraglutide a me Semaglutide.Front Endocrinol (Lausanne).2019 Apr 12; 10:155.
[5] Mahapatra MK, Karuppasamy M, Sahoo BM. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative maʻi: He Narrative Review.Pharm Res.2022 Jun;39(6 ):1233-1248.
